← Back to Home

From Suppressing Sleepiness to Rebuilding Wakefulness Signaling: Lundbeck’s New Narcolepsy Drug Granted FDA Fast Track Designation

The oral candidate Lu AH69593 directly activates the orexin type 2 receptor in an effort to address the dysregulated sleep–wake mechanism in narcolepsy; however, it remains in Phase 1 clinical development, and Fast Track designation does not mean that efficacy has been established.

By SURL BioNews

Narcolepsy treatment has long focused on alleviating symptoms such as excessive daytime sleepiness and cataplexy, but research is now gradually shifting toward the dysregulated wakefulness mechanism itself. The U.S. Food and Drug Administration (FDA) recently granted Fast Track designation to Lundbeck’s oral candidate Lu AH69593, giving this orexin receptor therapy an opportunity for closer communication with the regulator while still at an early stage of development.

Lu AH69593 is an orexin type 2 receptor (OX2R) agonist currently in late Phase 1 (Phase 1b) development. Orexin is a neuropeptide that helps maintain wakefulness and stabilize transitions between sleep and wakefulness; orexin neurons project to multiple brain regions that regulate arousal and rapid eye movement sleep. Direct activation of OX2R is intended to enhance wake-promoting signaling, rather than merely control individual symptoms through stimulant or sedative effects.

This approach has a particularly strong biological rationale in narcolepsy type 1, because orexin neurotransmission is markedly impaired in patients with this form of the condition. In addition to difficulty maintaining wakefulness, patients may experience cataplexy, fragmented nighttime sleep, sleep paralysis, and hallucinations. However, a mechanism of action that is “closer to the pathological root” does not automatically translate into better clinical outcomes. Whether the drug can provide sustained and stable daytime wakefulness while avoiding disruption of nighttime sleep and other physiological functions remains to be determined in trials.

European Union clinical trial data show that the relevant Phase 1 study is identified as EUCT 2024-511073-29-00. Sponsored by H. Lundbeck A/S, it is recruiting healthy adults and patients with narcolepsy aged 18 to 64 in Finland. The trial began on June 13, 2025, and as of May 2026, its registration status remained ongoing and recruiting. The EU and European Economic Area portion is estimated to be completed in December 2026.

The primary focus of this early-stage study remains safety and tolerability, rather than demonstrating therapeutic efficacy. Lundbeck’s announcement did not provide data on participant numbers, dosage, pharmacokinetics, wakefulness test results, or adverse events, and it is not yet possible to determine whether different narcolepsy subtypes will derive the same degree of benefit. In other words, although the candidate’s mechanism of action is clear, human evidence remains very limited.

The FDA Fast Track program applies to development programs for serious conditions with unmet medical needs. It can increase interaction with the FDA and, when eligibility requirements are met, expedite review through measures such as rolling submission. It is not marketing authorization and does not mean that the drug has passed assessments of efficacy or safety. The next truly critical milestone for Lu AH69593 will be whether the Phase 1 study can establish an acceptable safety range and generate preliminary pharmacological and clinical signals sufficient to support subsequent controlled trials.

References

  1. H. Lundbeck A/S
  2. PharmaTimes
  3. European Union Clinical Trials Information System